Edesa Biotech, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to CAD $23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company’s first-in-class therapeutic candidate.
Edesa is an alumnus of our WiHI program.